ASH 2021 Conference Coverage on VuMedi

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2021 Conference Coverage on VuMedi

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
COVID-19 and Blood Cancers

Playback speed

10 seconds

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients With R/R MF

By ASH 2021 Conference Coverage on VuMedi FEATURING Abdulraheem Yacoub

70 views

December 22, 2021

Comments 0

Moving Forward in Stage III/IV Classical Hodgkin Lymphoma

Feat. A. Ip

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

MDS and MPN

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

115 views

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

156 views

ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Studies:…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

311 views

ASH 2021 Clinical and Pathological Characteristics of Hypocellular M…

ASH 2021 Conference Coverage on VuMedi

K. Kim

152 views

ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis …

ASH 2021 Conference Coverage on VuMedi

E. Oliva

118 views

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …

ASH 2021 Conference Coverage on VuMedi

J. Bewersdorf

123 views

ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients…

ASH 2021 Conference Coverage on VuMedi

S. Verstovsek

97 views

ASH 2021 Updates on the Management of Polycythemia Vera

ASH 2021 Conference Coverage on VuMedi

A. Kuykendall

39 views

ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML…

ASH 2021 Conference Coverage on VuMedi

A. Jain

98 views

ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms…

ASH 2021 Conference Coverage on VuMedi

M. Shah

12 views

ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination …

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

13 views

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targete…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

70 views

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhib…

ASH 2021 Conference Coverage on VuMedi

A. Yacoub

67 views

ASH 2021 Highlights in MPN

ASH 2021 Conference Coverage on VuMedi

P. Bose

249 views

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

ASH 2021 Conference Coverage on VuMedi

M. Kremyanskaya

88 views

ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia …

ASH 2021 Conference Coverage on VuMedi

P. Bose

98 views

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

ASH 2021 Conference Coverage on VuMedi

F. Passamonti

141 views

ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Trea…

ASH 2021 Conference Coverage on VuMedi

J. Garcia

75 views

ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patien…

ASH 2021 Conference Coverage on VuMedi

A. Brunner

72 views

ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In P…

ASH 2021 Conference Coverage on VuMedi

H. Gill

477 views

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

52 views

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

Richard T. Silver

329 views

A Real-World Evaluation of the Association Between Elevated Blood Co…

Aaron Gerds

1.1K views

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemi…

ASH 2021 Conference Coverage on VuMedi

A. Tefferi

437 views

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

ASH 2021 Conference Coverage on VuMedi

J. Mascarenhas

617 views